SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Friedman MA, Carter SK. The therapy of osteogenic sarcoma. Current status and thoughts for future. J Surg Oncol. 1972; 4: 482510.
  • 2
    Marcove RC, Mike V, Hajek JV, et al. Osteogenic sarcoma under the age of twenty-one. J Bone Joint Surg. 1970; 52A: 411422.
  • 3
    Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314: 16001606.
  • 4
    Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992; 10: 515.
  • 5
    Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000; 18: 40164027.
  • 6
    Arndt CAS, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999; 341: 342352.
  • 7
    Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Clin Orthop. 1991; 270: 814.
  • 8
    Bramwell VHC, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992; 10: 15791591.
  • 9
    Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988; 6: 329337.
  • 10
    Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer. 1992; 69: 698708.
  • 11
    Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15: 7684.
  • 12
    Meyers PA, Garlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998; 16: 24522459.
  • 13
    Rosen G, Capparros B, Huvos M, et al. Pre-operative chemotherapy for osteosarcoma: selection of postoperative adjuvant chemotherapy base on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982; 49: 12211230.
  • 14
    Ward WG, Mikaelian K, Dorey F, et al. Pulmonary metastases of Stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994; 12: 18491858.
  • 15
    Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990; 8: 19881997.
  • 16
    Raymond AK. Osteosarcoma: specimen management after preoperative chemotherapy and arteriogram-directed dissection. Presented at Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multidisciplinary Approach, Houston Texas, November 2–5, 1988.
  • 17
    Marti C, Kroner T, Remagen W. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985; 69: 115117.
  • 18
    Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987; 71: 131135.
  • 19
    Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989; 7: 126131.
  • 20
    Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989; 7: 12081216.
  • 21
    Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991; 83: 14601470.
  • 22
    Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992; 10: 239253.
  • 23
    Kaplan EL, Meier R. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 24
    Sutow WW, Gehan EA, Dyment PG, et al. Multidrug adjuvant chemotherapy for osteosarcoma: interim report of the Southwest Oncology Group Studies. Cancer Treat Rep. 1978; 62: 265269.
  • 25
    Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities of trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776790.
  • 26
    Look AT, Douglass EC, Meyer WH. Clinical importance of near-diploid tumor stem lines in patients with osteosarcoma of an extremity. N Engl J Med. 1988; 318: 15671572.
  • 27
    Chan HSL, Grogan TM, Gaddad G, et al. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst. 1997; 89: 17061715.
  • 28
    Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol. 1996; 14: 467472.
  • 29
    Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999; 17: 27812788.
  • 30
    Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994; 12: 423431.
  • 31
    Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998; 16: 658663.
  • 32
    Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer. 2001; 37: 2030-–039.
  • 33
    Meyers P, Schwartz C, Bernstein M, et al. Addition of ifosfamide and muramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate improves event free survival (EFS) in localized osteosarcoma. Proc Am Soc Clin Oncol. 2001; 20: 1463.
  • 34
    Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol. 2001; 19: 171182.
  • 35
    Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995; 24: 8792.
  • 36
    Souhami RL, Craft AW, Van der Eijken JW,et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997; 350: 911917.
  • 37
    Cortes E, Necheles TF, Holland JF, et al. Adjuvant therapy of operable primary osteosarcoma: a Cancer and Leukemia Group B experience, In: SalmonS, JonesS, editors. Adjuvant therapy of cancer. Volume 3. New York: Grune & Stratton, 1981: 201210.
  • 38
    Krailo M, Ertel E, Makley J, et al. A randomized trial comparing high dose methotrexate with moderate dose methotrexate as components of adjuvant chemotherapy in childhood non-metastatic osteosarcoma. Med Pediatr Oncol. 1987; 15: 6977.
  • 39
    Lewis IJ, Weeden S, Machin D, et al. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. J Clin Oncol. 2000; 18: 40284037.